Organisation paid for research Program year 2025 Source: CMS Open Payments

Doctrials LLC

Neither a doctor nor a teaching hospital

Research payments

$4,724,470

832 payments

Through program year 2025, Doctrials LLC is reported as receiving $4,724,470 in research payments, across 832 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,377,116	360
2024	Research	$929,074	100
2023	Research	$454,796	59
2022	Research	$414,476	72
2021	Research	$718,552	80
2020	Research	$360,977	50
2019	Research	$469,478	111

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $1,881,152 309 payments
Ocular Therapeutix, Inc. $879,154 186 payments
Dompe Farmaceutici S.p.A. $451,271 29 payments
Novartis Pharmaceuticals Corporation $301,249 10 payments
Allergan Inc. $235,204 75 payments
Roche TCRC, Inc. $207,048 37 payments
Kala Pharmaceuticals, Inc. $198,360 42 payments
Sanofi US Services Inc. $126,799 26 payments
EyePoint Pharmaceuticals US, Inc. $75,049 3 payments
Apellis Pharmaceuticals, Inc. $64,413 15 payments

Studies the money was for Research payments · program years 2019–2025

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $879,154 186 payments
A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO) $451,271 29 payments
Port Delivery System of Ranibizumab Extension Study $377,490 46 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $315,948 38 payments
A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $240,875 3 payments
Entry Into Human of Ro7497372 in Participants With Diabetic MacUlar Edema $207,048 37 payments
A Phase 1 Sad MD in Diabetic MacUlar Edema $204,790 37 payments
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $198,360 42 payments
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $191,395 59 payments
Va2 Phiii Yosemite $184,176 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.